Abstract

Dilated cardiomyopathy (DCM) is a complex heart disease with a common phenotype but heterogeneous pathological mechanisms. It is defined as ventricular dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease. This heart disease shows a high prevalence, morbidity and mortality, being a major health problem. Early etiological diagnosis and prognosis stratification is crucial for the clinical management of the patient. Although imaging and genetic test avances have improved clinical practice, the diagnosis of the ethiology remains challenging. Novel accessible and veritable biomarkers are required. Advances in imaging technology and genetic tests have provided useful tools for clinical practice.
microRNAs (miRNAs), a group of small non-coding RNAs, have been established as key mediators of cell biology. Different cellular impairments, reponse to stress has been detected in a concentration impairment. Our previous research has suggested that the miRNA signature constitutes a novel source of non-invasive biomarkers for DCM, mainly for familial DCM. Several studies have reported the potential role of miRNAs as clinical indicators within the etiologies of DCM. But to our knowledge, none of them have been focused in DCM ethiology. I summarize the evidence of circulating miRNAs in DCM of different causes,- ischemic, familial and idiopathic,- and their usefulness in the development of novel diagnostic, prognostic and therapeutic approaches. Although the findings are still preliminary, miRNAs constitute a promising tool to assist in the clinical management of DCM. (Up to 250 words)

Biography

I am medical doctor, who has completed her PhD at the age of 26 years from Seville University and is Master of Science in novel imaging tools in cardiology diagnosis. My scientific activity has been focused on the fields of “Cardiomiopathies Diagnostics” and the “Molecular basis of Atherosclerosis”. I have a deep expertise in biomarker research, more specifically in the study of non-coding RNAs as biomarkers of cardiovascular-related conditions in the last five years. All my research lines have a strong translational perspective, from clinical needs to basic science. Focusing on my postdoctoral period, I have had both, a clinical and research activitiy. I have been asistant proffesor since 2009 at the Cadiz Medical School being involve in different national and international scientific commitees. I am author of several reviews based on non-coding RNA usefulness in cardiovascular diagnosis and excersise in which I discuss the clinical application of circulating non-coding RNAs and their potential technical and conceptual limitations (Up to 100 words)

X